Sulabh Engineers & Services Limited (BOM:508969)
India flag India · Delayed Price · Currency is INR
3.440
-0.060 (-1.71%)
At close: Aug 1, 2025

Verve Therapeutics Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Jul '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2016 - 2020
346339500343491147
Upgrade
Market Cap Growth
-32.33%-32.33%46.04%-30.27%234.93%108.57%
Upgrade
PE Ratio
10.6213.7535.1529.9954.7118.26
Upgrade
PS Ratio
6.095.9613.179.4213.135.91
Upgrade
PB Ratio
0.780.761.220.871.300.40
Upgrade
P/FCF Ratio
---23.61488.8813.24
Upgrade
P/OCF Ratio
---23.47201.4413.24
Upgrade
Debt / Equity Ratio
0.040.040.030.090.090.09
Upgrade
Debt / FCF Ratio
---2.3333.633.05
Upgrade
Quick Ratio
20.7520.75265.83119.1656.6341.16
Upgrade
Current Ratio
22.6822.68287.78122.8659.4244.87
Upgrade
Asset Turnover
0.130.130.090.090.090.06
Upgrade
Return on Equity (ROE)
7.61%7.61%4.35%3.82%2.97%2.94%
Upgrade
Return on Assets (ROA)
7.27%7.27%4.09%3.48%2.70%2.64%
Upgrade
Earnings Yield
7.12%7.27%2.84%3.33%1.83%5.48%
Upgrade
Earnings Yield
7.12%7.27%2.84%3.33%1.83%5.48%
Upgrade
FCF Yield
--1.92%-3.17%4.24%0.21%7.55%
Upgrade
Buyback Yield / Dilution
24.36%24.36%----
Upgrade
Source: S&P Global Market Intelligence. Financial Services template. Financial Sources.